After nearly a year of fighting to protect the patent on its blockbuster leukemia drug Gleevec, Novartis has made peace with Indian drugmaker Sun Pharma, reaching a settlement that will keep Sun's generic version off the U.S. market until February 2016, <em>Reuters</em> reports. Novartis' U.S. patent expires in July 2015.
written on 15.05.2014